Sayenko Kharenko advised on obtaining merger clearance for the acquisition of Millipore by Merck

Sayenko Kharenko antitrust team has provided legal assistance in a merger clearance before the Antimonopoly Committee of Ukraine (the “AMC”) for EUR 5.9 billion acquisition by Merck KGaA (“Merck”), a German pharmaceutical heavyweight, of Millipore Corporation (“Millipore”), a US developer of life science tools and services. Together, Millipore and Merck will have a significant presence in high-growth segments and an enhanced geographic presence. The combination of the research and development capabilities of both companies will create a powerful innovation platform to develop cutting-edge technologies tailored to the needs of customers. Merck Group is a group of research-driven pharmaceutical and chemical companies, headquartered in Darmstadt, Germany.

The Millipore Group, based in Billerica, Massachusetts, USA, is a global group of companies engaged in the development, production, and sale of life science tools and services. After examining the proposed transaction, the AMC has concluded that its implementation poses no threat to competition nor significantly limits competition on any product market in Ukraine.

Sayenko Kharenko competition team involved in the transaction included counsel Dmitry Taranyk and associate Valentyna Hvozd, led by partner Vladimir Sayenko.